Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Polymyxin B Hemoperfusion on Severe Sepsis Secondary to Pneumonia or Urinary Tract Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with septic shock defined by the third international consensus definitions for sepsis and septic shock~2. Newly diagnosed pneumonia or urinary tract infection (UTI) defined as the following:~   2-1. Pneumonia is defined by a new infiltrate on chest radiograph and the presence of one or several of the following signs or symptoms: cough, sputum production, dyspnea, core body temperature ≥ 38.0°C, auscultatory findings of abnormal breath sounds and rales and leukocyte count \> 10000 or \< 4000/L.~   2-2. UTI is defined by at least one clinical symptom (core body temperature ≥38.0°C, urinary urgency, polyuria, dysuria, suprapubic pain, flank pain, costovertebral angle tenderness, nausea and vomiting) and one urinary criterion (pyuria \>20 leukocytes/μL).~3. Hyperlactatemia (\>2 mmol/L)~4. Endotoxin activity assay (EAA) ≥ 0.5 units.~Exclusion Criteria:~1. Shock persisted \>12 hours before screening~2. Mechanical ventilation \>21 days~3. Uncontrolled hemorrhage~4. Thrombocytopenia (platelet count \< 30,000 cells/mm3)~5. Leukopenia (leukocyte count \< 1500 cells/mm3)~6. Suspected allergy to polymyxin~7. Females with pregnancy~8. Terminal cancer or organ failure with life expectancy less than 30 days

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention arm (Type: EXPERIMENTAL): Usual care with two sessions of 2-hour hemoperfusion with Toraymyxin in 24 hours apart

Based on this trial design, predict the completion outcome and termination type (if applicable).